Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.

Related Articles

Pentoxifylline and tocopherol in the management of cancer patients with medication-related osteonecrosis of the jaw: an observational retrospective study of initial case series.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2016 Oct;122(4):455-9

Authors: Owosho AA, Estilo CL, Huryn JM, Yom SK

Abstract
OBJECTIVE: Very few studies have evaluated the efficacy of pentoxifylline and tocopherol (PENT-E) in the management of medication-related osteonecrosis of the jaw (MRONJ), although some studies have shown the therapeutic and prophylactic benefit of PENT-E in the management of osteoradionecrosis. We report the outcomes of MRONJ managed with PENT-E in patients with metastatic bone disease or multiple myeloma.
STUDY DESIGN: Seven patients diagnosed with established cases of refractory MRONJ caused by antiresorptive medications for the management of metastatic bone tumors or multiple myeloma were administered PENT-E for a mean period of 16.8 months (range 3-48 months).
RESULTS: At the latest follow-up visit, all patients demonstrated relief of symptoms. There was radiographic evidence of new bone fill of prior radiolucent defect in all patients. Two patients had resolution of exposed bone, two patients had partial resolution, one patient had no change in exposed bone, and one patient with three sites of exposed bone before starting PENT-E had resolution in one site, partial resolution in another site, and no change in the third site. PENT-E was well tolerated in all patients.
CONCLUSIONS: Our case series demonstrated that PENT-E was well tolerated and may be an effective adjunct in the management of MRONJ.

PMID: 27651287 [PubMed - in process]

from #ORL via xlomafota13 on Inoreader http://ift.tt/2dlXMtP
via IFTTT